Nigeria to Roll Out Lenacapavir for HIV Prevention
Analysis based on 23 articles · First reported Mar 02, 2026 · Last updated Mar 03, 2026
The introduction of Lenacapavir in Nigeria is a positive development for the healthcare sector, particularly in HIV prevention. It signals a potential increase in market for Gilead Sciences' drug, especially with the partnerships making generic versions affordable in low- and middle-income countries. This could lead to improved public health outcomes and potentially reduce the economic burden of HIV treatment in Nigeria.
Nigeria is set to receive consignments of Lenacapavir, a new twice-yearly injectable drug for HIV prevention, in March 2026. The Nigeria===National Agency for the Control of AIDS (NACA) confirmed this development, highlighting the government's commitment to strengthening HIV prevention and accelerating progress towards epidemic control. Preparations are well underway, including regulatory clearance by the Nigeria===National Agency for Food and Drug Administration and Control (NAFDAC), landscape and readiness assessments in 10 states, and training for healthcare workers. Lenacapavir, developed by Gilead Sciences, offers a more convenient alternative to daily oral pills, with generic versions expected to be available at an affordable price of $40 annually in low- and middle-income countries, thanks to partnerships involving Unitaid and the Gates Foundation. Temitope Ilori, Director-General of NACA, has assured access to this groundbreaking drug, which has shown 100% effectiveness in preventing HIV infection in clinical trials.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard